Siemens launches new pediatric thyroid reference intervals for better patient care

May 14, 2015

Siemens Healthcare Diagnostics has launched new pediatric thyroid reference intervals for its ADVIA Centaur Systems, Dimension Vista Systems and Dimension EXL Systems to enhance the interpretation of thyroid assay testing in children and optimize patient care. Thyroid disease in children is associated with impaired physical and cognitive development.


“Siemens is proud to deliver these valuable new pediatric reference intervals for our ADVIA Centaur and Dimension systems as a service to our customers to support their efforts in providing optimal care for their young patients,” said Franz Walt, CEO, Chemistry, Immunoassay, Automation and Diagnostics IT Business Unit, Siemens Healthcare Diagnostics. “These new pediatric thyroid reference intervals were established based on a robust, multi-site study for three age groups: 1-23 months, 2-12 years and 13-20 years.”


Age specific reference intervals are critical for proper interpretation of test results in the pediatric population. Unfortunately, there are few studies that provide this information, and hospital laboratories often find it challenging to establish their own pediatric reference intervals due to resourcing issues, lack of sufficient, well-characterized samples and blood-volume constraints. Also, general published intervals are not always true for each instrument and assay. This makes instrument and assay-method specific pediatric reference intervals critical to the accurate interpretation of thyroid results.


To establish the new pediatric reference intervals, Siemens conducted a study of over 400 pediatric samples collected from eight sites across the United States. Reference intervals were established across genders, and the study included an approximately equal number of males and females. Siemens used stringent inclusion criteria for well-characterized subject selection and a statistical package recommended by the Clinical and Laboratory Standards Institute (CLSI) and well-established worldwide guidelines for establishing reference intervals in laboratory testing (Horn and Pesce).


For further information on Siemens thyroid solutions, please visit:



Contact for journalists:

Susan Drew
Siemens Healthcare, Media Relations
Phone: +1 914-524-2844; E-mail:
Follow us on Twitter at:


The products/features (here mentioned) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Further details are available from the local Siemens organizations.


Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2014, which ended on September 30, 2014, Siemens generated revenue from continuing operations of €71.9 billion and net income of €5.5 billion. At the end of September 2014, the company had around 357,000 employees worldwide. Further information is available on the Internet at

Related Articles